Overview

Cardiovascular Inflammation Reduction Trial

Status:
Completed
Trial end date:
2019-10-30
Target enrollment:
Participant gender:
Summary
The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages. This trial is funded by the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH).
Phase:
Phase 3
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Methotrexate